RecruitingNCT06606314
Specified Drug-use Surveillance of Fabhalta Capsules
Specified Drug-use Surveillance of Fabhalta Capsules (Paroxysmal Nocturnal Hemoglobinuria, CLNP023C11401)
Sponsor
Novartis Pharmaceuticals
Enrollment
100 participants
Start Date
Sep 18, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a multicenter, single-arm, non-interventional study (NIS) with a central registration system and an all-case surveillance system. The observation period is 48 weeks after the start of treatment with Fabhalta.
Eligibility
Min Age: 0 YearsMax Age: 100 Years
Inclusion Criteria2
- All patients who received Fabhalta.
- ·
Exclusion Criteria1
- Patients receiving Fabhalta for an unapproved indication under the Clinical Trials Act or GCP.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(92)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06606314
Related Trials
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT071547458 locations
Danicopan PMS in Korea
NCT074571514 locations
Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT074707621 location
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT0574492143 locations
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT064490014 locations